Breaking the Diabesity Cycle: Unveiling New Research on Obesity and Diabetes
October 17, 2024
Obesity and diabetes are two of the most pressing health challenges facing society today, impacting millions and often occurring hand in hand. As obesity rates have soared to epidemic levels, Type 2 diabetes has followed suit. While researchers have long known of this connection, only recently have they begun to uncover the complex mechanisms linking […]
Meet Biocytogen at Bio-Europe 2024!
October 15, 2024
Biocytogen (HKEX: 02315) is excited to attend Bio-Europe 2024 in Stockholm, Sweden, from November 4-6! Our Business Development Team is excited to meet you in person at Booth #74! Schedule a 1-on-1 meeting with us, and stop by to discover our innovative solutions in antibody drug discovery! RenBiologics – Our fully human library. Your pipeline. Developed using our […]
Unlocking the Autism Puzzle: Genes, Minds, and Untold Possibilities
October 4, 2024
Autism Spectrum Disorder (ASD), often identified in early childhood, presents challenges in social interactions, communication, and repetitive behaviors. The term “spectrum” reflects the wide range of abilities, with some individuals displaying exceptional skills, while others face significant difficulties, such as non-verbal communication, aggression, epilepsy, and self-injury. Sometimes referred to as “children of the stars,” individuals […]
The Blood-Brain Barrier: A Double-Edged Sword in Neurology
September 17, 2024
The brain, our most intricate and vital organ, is safeguarded by a unique structure known as the blood-brain barrier (BBB). Acting as a fortress, the BBB keeps harmful substances out while preserving the delicate environment of the brain. This protective mechanism, however, also poses significant challenges in developing drugs for the central nervous system (CNS). […]
Charting New Frontiers in GvHD Treatment: Insights from Niktimvo™ FDA approval
September 4, 2024
On August 14, 2024, Syndax and Incyte announced the FDA approval of Niktimvo™ (axatilimab-csfr), a CSF-1R monoclonal antibody, for the treatment of chronic graft-versus-host disease (GvHD). Axatilimab is the first CSF-1R monoclonal antibody to receive approval, specifically targeting the drivers of inflammation and fibrosis in chronic GvHD (Business Wire, 2024). CSF-1R, a cell surface protein, […]
Conquering the Inner Struggle: Mastering Autoimmune and Inflammatory Diseases
August 15, 2024
It’s well-known that a robust immune system is fundamental to good health. Yet, did you know that our immune system, designed to protect us, can sometimes turn against us, attacking the body itself? This troubling issue lies at the heart of autoimmune diseases. In these conditions, the immune system mistakenly targets healthy tissues, causing inflammation […]
From Target to Therapeutics with Humanized Mouse Models
July 29, 2024
Ever wondered how cutting-edge medical research translates lab findings into real-world treatments? At the forefront of this transformation are humanized mice. These lab partners are engineered to carry human elements such as DNA, cells, and immune systems, among others. By incorporating human biological components, humanized mouse models provide a more accurate simulation of human physiological […]
Breaking New Ground in Alzheimer’s Treatment: A Deep Dive into Lilly’s Kisunla™ (Donanemab-azbt) FDA Approval
July 16, 2024
The recent FDA approval of Lilly’s Kisunla™ (donanemab-azbt) for early symptomatic Alzheimer’s disease marks a monumental breakthrough in combating this debilitating condition. As we celebrate this achievement, it’s crucial to explore its implications and highlight how our innovative humanized mouse models contribute to advancing Alzheimer’s research. Kisunla™ targets the amyloid plaques that accumulate in the […]